Investigating outcomes and treatment of long coronavirus disease 2019 in patients with multiple sclerosis treated with rituximab: A case series study
Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, characterized by the destruction of the myelin sheath of nerves. MS patients treated with rituximab, an immunosuppressive drug, experience reduced immunoglobulin levels, which increases their risk of variou...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-05-01
|
| Series: | Journal of Research in Medical Sciences |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jrms.jrms_150_25 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850133124880531456 |
|---|---|
| author | Kiana Shirani Farzin Khorvash Alireza Karamshahi Asieh Maghamimehr |
| author_facet | Kiana Shirani Farzin Khorvash Alireza Karamshahi Asieh Maghamimehr |
| author_sort | Kiana Shirani |
| collection | DOAJ |
| description | Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, characterized by the destruction of the myelin sheath of nerves. MS patients treated with rituximab, an immunosuppressive drug, experience reduced immunoglobulin levels, which increases their risk of various infections, including coronavirus disease 2019 (COVID-19). During the COVID-19 pandemic, many of these patients developed long-term symptoms following infection. These chronic symptoms have led to significant complications and, in some cases, increased mortality. In this case series study, we investigated long COVID-19 symptoms in MS patients treated with rituximab and the effects of intravenous immunoglobulin (IVIG) therapy in alleviating chronic symptoms. The results demonstrated that the patients’ long-term symptoms responded to IVIG treatment, with significant improvements in respiratory symptoms, fever, immune parameters, and a reduction in C-reactive protein levels. This study highlights the importance of targeted management of long COVID-19 in immunocompromised populations and suggests that COVID-19 patients with immune deficiencies require specific therapeutic approaches. |
| format | Article |
| id | doaj-art-aa5da0c9900a406b91922f280eb26dc3 |
| institution | OA Journals |
| issn | 1735-1995 1735-7136 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Research in Medical Sciences |
| spelling | doaj-art-aa5da0c9900a406b91922f280eb26dc32025-08-20T02:32:04ZengWolters Kluwer Medknow PublicationsJournal of Research in Medical Sciences1735-19951735-71362025-05-01301262610.4103/jrms.jrms_150_25Investigating outcomes and treatment of long coronavirus disease 2019 in patients with multiple sclerosis treated with rituximab: A case series studyKiana ShiraniFarzin KhorvashAlireza KaramshahiAsieh MaghamimehrMultiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, characterized by the destruction of the myelin sheath of nerves. MS patients treated with rituximab, an immunosuppressive drug, experience reduced immunoglobulin levels, which increases their risk of various infections, including coronavirus disease 2019 (COVID-19). During the COVID-19 pandemic, many of these patients developed long-term symptoms following infection. These chronic symptoms have led to significant complications and, in some cases, increased mortality. In this case series study, we investigated long COVID-19 symptoms in MS patients treated with rituximab and the effects of intravenous immunoglobulin (IVIG) therapy in alleviating chronic symptoms. The results demonstrated that the patients’ long-term symptoms responded to IVIG treatment, with significant improvements in respiratory symptoms, fever, immune parameters, and a reduction in C-reactive protein levels. This study highlights the importance of targeted management of long COVID-19 in immunocompromised populations and suggests that COVID-19 patients with immune deficiencies require specific therapeutic approaches.https://journals.lww.com/10.4103/jrms.jrms_150_25hypogammaglobulinemiaintravenous immunoglobulinlong coronavirus disease 2019multiple sclerosisrituximab |
| spellingShingle | Kiana Shirani Farzin Khorvash Alireza Karamshahi Asieh Maghamimehr Investigating outcomes and treatment of long coronavirus disease 2019 in patients with multiple sclerosis treated with rituximab: A case series study Journal of Research in Medical Sciences hypogammaglobulinemia intravenous immunoglobulin long coronavirus disease 2019 multiple sclerosis rituximab |
| title | Investigating outcomes and treatment of long coronavirus disease 2019 in patients with multiple sclerosis treated with rituximab: A case series study |
| title_full | Investigating outcomes and treatment of long coronavirus disease 2019 in patients with multiple sclerosis treated with rituximab: A case series study |
| title_fullStr | Investigating outcomes and treatment of long coronavirus disease 2019 in patients with multiple sclerosis treated with rituximab: A case series study |
| title_full_unstemmed | Investigating outcomes and treatment of long coronavirus disease 2019 in patients with multiple sclerosis treated with rituximab: A case series study |
| title_short | Investigating outcomes and treatment of long coronavirus disease 2019 in patients with multiple sclerosis treated with rituximab: A case series study |
| title_sort | investigating outcomes and treatment of long coronavirus disease 2019 in patients with multiple sclerosis treated with rituximab a case series study |
| topic | hypogammaglobulinemia intravenous immunoglobulin long coronavirus disease 2019 multiple sclerosis rituximab |
| url | https://journals.lww.com/10.4103/jrms.jrms_150_25 |
| work_keys_str_mv | AT kianashirani investigatingoutcomesandtreatmentoflongcoronavirusdisease2019inpatientswithmultiplesclerosistreatedwithrituximabacaseseriesstudy AT farzinkhorvash investigatingoutcomesandtreatmentoflongcoronavirusdisease2019inpatientswithmultiplesclerosistreatedwithrituximabacaseseriesstudy AT alirezakaramshahi investigatingoutcomesandtreatmentoflongcoronavirusdisease2019inpatientswithmultiplesclerosistreatedwithrituximabacaseseriesstudy AT asiehmaghamimehr investigatingoutcomesandtreatmentoflongcoronavirusdisease2019inpatientswithmultiplesclerosistreatedwithrituximabacaseseriesstudy |